Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Key facts
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jan 2026
- Ended
- 19 Jan 2026
- Type of study
- Observational
- Record updated
- 3 March 2026
- Why it stopped
- The study team decided to not move forward with enrolling patients because funding was not identified to support the project.
Who can take part
- Age
- 18 years to 100 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Newly diagnosed prostate cancer within the past 12 months:
- The patient has decided to undergo brachytherapy as treatment modality for his prostate cancer
- Suitable volume of disease for biopsy, defined as one or more of the following:; Identifiable lesions of greater or equal to one; Clinically palpable disease corresponding to (ipsilateral to) any involved core on biopsy OR; ≥50% of biopsy cores involved with cancer
- Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures
- Males 18 years of age or older
- Signed study-specific consent form prior to registration
Who cannot take part
- Prior history of any other malignancy which was either newly diagnosed or recurred (following prior curative treatment) within last 2 years, other than non-melanoma skin carcinoma
- Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up
Where in United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimore, United States
About the trial
What the trial wants to find out
The primary goal of this tissue collection protocol is to establish a framework for the acquisition and banking of biospecimen collected from men undergoing brachytherapy. Biopsies of the prostate is an invasive procedure; however, in this tissue collection protocol, biopsies are acquired intraoperatively while patients are prepped for brachytherapy seed placement, thus minimizing the inconvenience of the biopsy procedure for patients. The utility of these biopsies will provide a valuable resource for molecular assessments.
The group in the trial
- Prostate Biopsy, Urine sample and Blood sample
For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prostate Tissue Biopsy Collection for Men Undergoing Brachytherapy for Treatment of Localized or Locally Advanced Prostate Cancer
- Record updated
- 3 March 2026